A. Nelstrop

发表

Use of CA-125 to predict survival of patients with ovarian carcinoma. North Thames Cooperative Group.

G. Rustin, J. Gennings, A. Nelstrop, 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Use of tumour markers in monitoring the course of ovarian cancer.

S M Bentzen, M. Piccart, G. Rustin, 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

POMB/ACE chemotherapy for mediastinal germ cell tumours.

C. Brock, G. Rustin, M. Bower, 1997, European journal of cancer.

Characterisation of Staphylococcus argenteus carried by healthy Royal Marines: a molecular epidemiology case-study

J. Fallowfield, S. Sriskandan, B. Pichon, 2021, medRxiv.

Specific tubercle antigen

E. Nassau, A. Nelstrop, 1976 .

Savings obtained by CA-125 measurements during therapy for ovarian carcinoma. The North Thames Ovary Group.

J. Stilwell, G. Rustin, A. Nelstrop, 1992, European journal of cancer.

Use of tumour markers in monitoring the course of ovarian cancer.

M. Piccart, G. Rustin, S. Bentzen, 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

A randomized trial of five versus eight courses of cisplatin or carboplatin in advanced epithelial ovarian carcinoma* A Ovary

W. Gregory, G. Rustin, A. Nelstrop, 2005 .

Phase II trial of oral altretamine for relapsed ovarian carcinoma: evaluation of defining response by serum CA125.

G. Rustin, W. Oster, J. Ledermann, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Comparative studies of serum and haemolymph proteins.

A. Nelstrop, P. Collard, G. Taylor, 1970, Comparative biochemistry and physiology.

Treatment of advanced malignant melanoma with interferon alpha and etretinate.

G. Rustin, S. Dische, A. Nelstrop, 1988, European journal of cancer & clinical oncology.

Studies on phagocytosis. 3. Antigen clearance studies in invertebrates and poikilothermic vertebrates.

A. Nelstrop, P. Collard, G. Taylor, 1968, Immunology.

Defining progression of ovarian carcinoma during follow-up according to CA 125: a North Thames Ovary Group Study.

G. Rustin, M. Tuxen, A. Nelstrop, 1996, Annals of oncology : official journal of the European Society for Medical Oncology.

Comparison of CA-125 and standard definitions of progression of ovarian cancer in the intergroup trial of cisplatin and paclitaxel versus cisplatin and cyclophosphamide.

M. Piccart, E. Eisenhauer, G. Rustin, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase II study of sequential carboplatin, paclitaxel and topotecan in patients with previously untreated advanced ovarian cancer

G. Rustin, M. Seckl, R. Agarwal, 2004, British Journal of Cancer.

Weekly cisplatin and oral etoposide as treatment for relapsed epithelial ovarian cancer.

T. Meyer, G. Rustin, M. Mahmoudi, 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

Use of CA-125 to define progression of ovarian cancer in patients with persistently elevated levels.

G. Rustin, T. Meyer, M. Marples, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

U s e o f CA-125 t o D efine P rogression o f O varian C ancer i n Patients W ith P ersistently E levated L evels

G. Rustin, T. Meyer, M. Marples, 2001 .

Comparison of standard and CA-125 response criteria in patients with epithelial ovarian cancer treated with platinum or paclitaxel.

M. Gore, G. Rustin, J. Bridgewater, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Trial of isotretinoin and calcitriol monitored by CA 125 in patients with ovarian cancer.

G. Rustin, W. Bollag, A. Nelstrop, 1996, British Journal of Cancer.

A randomized trial of five versus eight courses of cisplatin or carboplatin in advanced epithelial ovarian carcinoma. A North Thames Ovary Group Study.

W. Gregory, G. Rustin, A. Nelstrop, 1997, Annals of oncology : official journal of the European Society for Medical Oncology.

The prognostic value of serum CA 125 in patients with advanced ovarian carcinoma: an analysis of 573 patients by the Medical Research Council Working Party on Gynaecological Cancer

D. Cruickshank, C. Redman, D. Parker, 1992, International Journal of Gynecologic Cancer.

Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125.

H E Lambert, G. Rustin, G. Rustin, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Outcome of epithelial ovarian cancer in women under 40 years of age treated with platinum-based chemotherapy.

J. Ledermann, G. Rustin, J. Ledermann, 1999, European journal of cancer.

Studies on phagocytosis. II. In vitro phagocytosis by macrophages.

A. Nelstrop, P. Collard, G. Taylor, 1968, Immunology.

Selection of active drugs for ovarian cancer based on CA-125 and standard response rates in phase II trials.

G. Rustin, S. Bentzen, S. Bond, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Biological variation and analytical imprecision of CA 125 in patients with ovarian cancer

P. Dombernowsky, G. Rustin, G. Sölétormos, 2000, Scandinavian journal of clinical and laboratory investigation.

A randomized trial comparing single-agent carboplatin with carboplatin followed by radiotherapy for advanced ovarian cancer: a North Thames Ovary Group study.

W. Gregory, G. Rustin, A. Nelstrop, 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The detection by immunofluorescence of casein in rat mammary glands.

A. Nelstrop, S. Young, 1970, British journal of experimental pathology.

Long-term survival in 463 women treated with platinum analogs for advanced epithelial carcinoma of the ovary: life expectancy compared to women of an age-matched normal population

W. Gregory, G. Rustin, A. Nelstrop, 2003, International Journal of Gynecologic Cancer.

Long‐term survival in 463 women treated with platinum analogs for advanced epithelial carcinoma of the ovary: life expectancy compared to women of an age‐matched normal population

W. Gregory, G. Rustin, A. Nelstrop, 2004, International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.

FaFEC: a novel regimen for advanced ovarian cancer.

G. Rustin, M. Bower, K. Goodchild, 1997, International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.